Teneligliptin (BioDeep_00000752581)
代谢物信息卡片
Teneligliptin
化学式: C22H30N6OS (426.220169)
中文名称: 特力利汀
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=NN(C(=C1)N2CCN(CC2)C3CC(NC3)C(=O)N4CCSC4)C5=CC=CC=C5
InChI: InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1
描述信息
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:136042
- KEGGdrug: D08616
- PubChem: 11949652
- DrugBank: DB11950
- ChEMBL: CHEMBL2147777
- CAS: 906093-29-6
- CAS: 760937-92-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Satoko Kawarasaki, Honami Sawazaki, Hiroaki Iijima, Haruya Takahashi, Wataru Nomura, Kazuo Inoue, Teruo Kawada, Tsuyoshi Goto. Combined treatment with teneligliptin and canagliflozin additively suppresses high-fat diet-induced body weight gain in mice with modulation of lipid metabolism-related gene expression.
European journal of pharmacology.
2023 May; 947(?):175682. doi:
10.1016/j.ejphar.2023.175682. [PMID: 36965744] - Hongliang Li, Jin Ryeol An, Minju Park, Jaehee Choi, Ryeon Heo, Minji Kang, Seo-Yeong Mun, Wenwen Zhuang, Mi Seon Seo, Eun-Taek Han, Jin-Hee Han, Wanjoo Chun, Won Sun Park. The antidiabetic drug teneligliptin induces vasodilation via activation of PKG, Kv channels, and SERCA pumps in aortic smooth muscle.
European journal of pharmacology.
2022 Nov; 935(?):175305. doi:
10.1016/j.ejphar.2022.175305. [PMID: 36183856] - Banshi Saboo, Sujoy Ghosh, Mangesh Tiwaskar, Rajeev Chawla. QTc prolongation Safety and Effectiveness of Teneligliptin in Indian patients with type 2 Diabetes Mellitus: A real world study (QSET 2).
Diabetes & metabolic syndrome.
2021 Sep; 15(5):102264. doi:
10.1016/j.dsx.2021.102264. [PMID: 34488059] - Ashit Syngle, Simran Chahal, Kanchan Vohra. Efficacy and tolerability of DPP4 inhibitor, teneligliptin, on autonomic and peripheral neuropathy in type 2 diabetes: an open label, pilot study.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.
2021 Apr; 42(4):1429-1436. doi:
10.1007/s10072-020-04681-2. [PMID: 32803534] - Linong Ji, Ling Li, Jianhua Ma, Xuefeng Li, Dongmei Li, Bangzhu Meng, Weiping Lu, Jiao Sun, Yanmei Liu, Gen Takayanagi, Yi Wang. Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled study.
Endocrinology, diabetes & metabolism.
2021 04; 4(2):e00222. doi:
10.1002/edm2.222. [PMID: 33855222] - Subhankar Chowdhury, Manoj Chadha, Sujoy Ghosh, Anirban Majumder, Debmalya Sanyal, Soumik Goswami, Debasis Giri, Arjun Baidya, P K Sahana, Anirban Sinha, Animesh Maiti, Rana Bhattacharjee, Ajitesh Roy, Sambit Das. Indian Expert Review on Use of Teneligliptin in patients with Diabetes and its Safety and Efficacy (INTENSE).
The Journal of the Association of Physicians of India.
2021 Jan; 69(1):61-70. doi:
NULL. [PMID: 34227778] - Kazumi Mori-Anai, Yoshihiko Tashima, Tomohisa Nakada, Yoshinobu Nakamaru, Takayuki Takahata, Ryuta Saito. Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
Biopharmaceutics & drug disposition.
2020 Nov; 41(8-9):352-366. doi:
10.1002/bdd.2253. [PMID: 33085977] - Yoshimasa Aso, Masato Kase, Masaaki Sagara, Shintaro Sakurai, Toshie Iijima, Takuya Tomaru, Teruo Jojima, Isao Usui. Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes.
The American journal of the medical sciences.
2020 09; 360(3):261-267. doi:
10.1016/j.amjms.2020.05.005. [PMID: 32540146] - Guang Wang, Bing Wu, Yang Cui, Bo Zhang, Chunyan Jiang, Heyuan Wang. Teneligliptin Promotes Bile Acid Synthesis and Attenuates Lipid Accumulation in Obese Mice by Targeting the KLF15-Fgf15 Pathway.
Chemical research in toxicology.
2020 08; 33(8):2164-2171. doi:
10.1021/acs.chemrestox.0c00192. [PMID: 32639145] - Yayoi Nishida, Yasuo Takahashi, Kotoe Tezuka, Hayato Akimoto, Tomohiro Nakayama, Satoshi Asai. Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus.
BMC pharmacology & toxicology.
2020 04; 21(1):28. doi:
10.1186/s40360-020-00407-4. [PMID: 32317005] - Kosuke Okabe, Shouji Matsushima, Soichiro Ikeda, Masataka Ikeda, Akihito Ishikita, Tomonori Tadokoro, Nobuyuki Enzan, Taishi Yamamoto, Masashi Sada, Hiroko Deguchi, Keisuke Shinohara, Tomomi Ide, Hiroyuki Tsutsui. DPP (Dipeptidyl Peptidase)-4 Inhibitor Attenuates Ang II (Angiotensin II)-Induced Cardiac Hypertrophy via GLP (Glucagon-Like Peptide)-1-Dependent Suppression of Nox (Nicotinamide Adenine Dinucleotide Phosphate Oxidase) 4-HDAC (Histone Deacetylase) 4 Pathway.
Hypertension (Dallas, Tex. : 1979).
2020 04; 75(4):991-1001. doi:
10.1161/hypertensionaha.119.14400. [PMID: 32160098] - Takahiro Ozutsumi, Tadashi Namisaki, Naotaka Shimozato, Kosuke Kaji, Yuki Tsuji, Daisuke Kaya, Yukihisa Fujinaga, Masanori Furukawa, Keisuke Nakanishi, Shinya Sato, Yasuhiko Sawada, Soichiro Saikawa, Koh Kitagawa, Hiroaki Takaya, Hideto Kawaratani, Mitsuteru Kitade, Kei Moriya, Ryuichi Noguchi, Takemi Akahane, Akira Mitoro, Hitoshi Yoshiji. Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis.
International journal of molecular sciences.
2020 Mar; 21(6):. doi:
10.3390/ijms21062164. [PMID: 32245205] - Jin-Woo Park, Kyoung-Ah Kim, Ji-Young Park. Development of a liquid chromatography/tandem-mass spectrometry assay for the simultaneous determination of teneligliptin and its active metabolite teneligliptin sulfoxide in human plasma.
Biomedical chromatography : BMC.
2020 Feb; 34(2):e4721. doi:
10.1002/bmc.4721. [PMID: 31656058] - Yosuke Takamiya, Keisuke Okamura, Kazuyuki Shirai, Tetsu Okuda, Kunihisa Kobayashi, Hidenori Urata. Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T).
Clinical and experimental hypertension (New York, N.Y. : 1993).
2020; 42(3):197-204. doi:
10.1080/10641963.2019.1601207. [PMID: 30974980] - Sanjay Sharma, Raksha Sharma, Ketan Hatware, Kiran Patil. Review on Chemistry, Analysis and Pharmacology of Teneligliptin: A Novel DPP-4 Inhibitor.
Mini reviews in medicinal chemistry.
2020; 20(12):1091-1100. doi:
10.2174/1389557520666200228144148. [PMID: 32107992] - Jin-Woo Park, Kyoung-Ah Kim, Yun Jung Choi, Soo Hyun Yoon, Ji-Young Park. Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects.
Journal of clinical pharmacy and therapeutics.
2019 Oct; 44(5):720-725. doi:
10.1111/jcpt.12848. [PMID: 31094010] - Davide Viggiano, Anna Capasso, Giovambattista Capasso. A quest for protecting kidneys from cisplatin toxicity.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2019 10; 34(10):1623-1625. doi:
10.1093/ndt/gfz029. [PMID: 30815681] - Takamasa Iwakura, Zhibo Zhao, Julian A Marschner, Satish Kumar Devarapu, Hideo Yasuda, Hans Joachim Anders. Dipeptidyl peptidase-4 inhibitor teneligliptin accelerates recovery from cisplatin-induced acute kidney injury by attenuating inflammation and promoting tubular regeneration.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2019 10; 34(10):1669-1680. doi:
10.1093/ndt/gfy397. [PMID: 30624740] - Yuta Takagaki, Sen Shi, Makoto Katoh, Munehiro Kitada, Keizo Kanasaki, Daisuke Koya. Dipeptidyl peptidase-4 plays a pathogenic role in BSA-induced kidney injury in diabetic mice.
Scientific reports.
2019 05; 9(1):7519. doi:
10.1038/s41598-019-43730-5. [PMID: 31101909] - Antonio Ceriello, Valeria De Nigris, Hiroaki Iijima, Takahiro Matsui, Maki Gouda. The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.
Drugs.
2019 May; 79(7):733-750. doi:
10.1007/s40265-019-01086-0. [PMID: 30982160] - Munehiro Kitada, Yoshio Ogura, Kyoko Nitta, Mizue Fujii, Keizo Kanasaki, Kazunori Konishi, Yasuo Iida, Atsushi Nakagawa, Daisuke Koya. Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease.
Journal of diabetes investigation.
2019 May; 10(3):706-713. doi:
10.1111/jdi.12917. [PMID: 30136384] - Yonghyun Kim, Eun Seok Kang, Hak Chul Jang, Dong Jun Kim, Taekeun Oh, Eun Sook Kim, Nan-Hee Kim, Kyung Mook Choi, Sung-Rae Kim, JiYoung You, Se-Jin Kim, Moon-Kyu Lee. Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
Diabetes, obesity & metabolism.
2019 03; 21(3):631-639. doi:
10.1111/dom.13566. [PMID: 30362280] - Sumie Okahata, Kentaro Sakamoto, Takako Mitsumatsu, Yuko Kondo, Shoji Tanaka, Teruo Shiba. Mechanistic insights from sequential combination therapy with a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin.
Diabetes, obesity & metabolism.
2019 02; 21(2):388-392. doi:
10.1111/dom.13505. [PMID: 30146790] - Yusuke Takahara, Tomotake Tokunou, Toshihiro Ichiki. Suppression of Abdominal Aortic Aneurysm Formation in Mice by Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor.
Journal of atherosclerosis and thrombosis.
2018 Aug; 25(8):698-708. doi:
10.5551/jat.42481. [PMID: 29321388] - Masakazu Haneda, Takashi Kadowaki, Hiroshi Ito, Kazuyo Sasaki, Sonoe Hiraide, Manabu Ishii, Miyuki Matsukawa, Makoto Ueno. Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.
Diabetes therapy : research, treatment and education of diabetes and related disorders.
2018 Jun; 9(3):1083-1097. doi:
10.1007/s13300-018-0416-2. [PMID: 29637459] - Priyanka A Shah, Pranav S Shrivastav, Pravin G Vanol, Mallika Sanyal. Mechanistic study for the simultaneous determination of metformin and teneligliptin in human plasma using hydrophilic interaction liquid chromatography-MS/MS.
Bioanalysis.
2018 Apr; 10(7):475-488. doi:
10.4155/bio-2018-0007. [PMID: 29561645] - Takashi Kadowaki, Nobuya Inagaki, Kazuoki Kondo, Kenichi Nishimura, Genki Kaneko, Nobuko Maruyama, Nobuhiro Nakanishi, Yumi Watanabe, Maki Gouda, Hiroaki Iijima. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
Diabetes, obesity & metabolism.
2018 01; 20(1):77-84. doi:
10.1111/dom.13038. [PMID: 28608617] - Akira Kurozumi, Yosuke Okada, Kei Sugai, Keiichi Torimoto, Yoshiya Tanaka. Comparison of the Effects of Teneligliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus.
Journal of UOEH.
2018 ; 40(1):1-9. doi:
10.7888/juoeh.40.1. [PMID: 29553070] - David Paul, Lingesh Allakonda, Nanjappan Satheeshkumar. A validated UHPLC-QTOF-MS method for quantification of metformin and teneligliptin in rat plasma: Application to pharmacokinetic interaction study.
Journal of pharmaceutical and biomedical analysis.
2017 Sep; 143(?):1-8. doi:
10.1016/j.jpba.2017.05.026. [PMID: 28544884] - Koichiro Homma, Joe Yoshizawa, Yutaka Shiina, Hideki Ozawa, Muneki Igarashi, Tadashi Matsuoka, Junichi Sasaki, Mamoru Yoshizawa, Yasuhiko Homma. A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis.
Drugs in R&D.
2017 Sep; 17(3):397-402. doi:
10.1007/s40268-017-0189-5. [PMID: 28577292] - Hotimah Masdan Salim, Daiju Fukuda, Yasutomi Higashikuni, Kimie Tanaka, Yoichiro Hirata, Shusuke Yagi, Takeshi Soeki, Michio Shimabukuro, Masataka Sata. Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice.
Vascular pharmacology.
2017 09; 96-98(?):19-25. doi:
10.1016/j.vph.2017.03.003. [PMID: 28347868] - Takashi Kadowaki, Nobuya Inagaki, Kazuoki Kondo, Kenichi Nishimura, Genki Kaneko, Nobuko Maruyama, Nobuhiro Nakanishi, Hiroaki Iijima, Yumi Watanabe, Maki Gouda. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
Diabetes, obesity & metabolism.
2017 06; 19(6):874-882. doi:
10.1111/dom.12898. [PMID: 28177187] - Fumitaka Okajima, Tomoko Nagamine, Yuko Nakamura, Naomi Hattori, Hitoshi Sugihara, Naoya Emoto. Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study.
Journal of diabetes investigation.
2017 May; 8(3):341-345. doi:
10.1111/jdi.12588. [PMID: 27762088] - Takahiro Oguma, Chiaki Kuriyama, Keiko Nakayama, Yasuaki Matsushita, Kumiko Hikida, Minoru Tsuda-Tsukimoto, Akira Saito, Kenji Arakawa, Kiichiro Ueta, Masabumi Minami, Masaharu Shiotani. Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium-glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents.
Journal of pharmacological sciences.
2016 Dec; 132(4):255-261. doi:
10.1016/j.jphs.2016.10.006. [PMID: 27889414] - Takehiro Hashikata, Minako Yamaoka-Tojo, Ryota Kakizaki, Teruyoshi Nemoto, Kazuhiro Fujiyoshi, Sayaka Namba, Lisa Kitasato, Takuya Hashimoto, Ryo Kameda, Emi Maekawa, Takao Shimohama, Taiki Tojo, Junya Ako. Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes.
Heart and vessels.
2016 Aug; 31(8):1303-10. doi:
10.1007/s00380-015-0724-7. [PMID: 26266630] - Masaaki Sagara, Kunihiro Suzuki, Chie Aoki, Seiichi Tanaka, Isao Taguchi, Teruo Inoue, Yoshimasa Aso. Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study.
Cardiovascular diabetology.
2016 May; 15(?):76. doi:
10.1186/s12933-016-0396-3. [PMID: 27184495] - S Hong, C-Y Park, K A Han, C H Chung, B J Ku, H C Jang, C W Ahn, M-K Lee, M K Moon, H S Son, C B Lee, Y-W Cho, S-W Park. Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.
Diabetes, obesity & metabolism.
2016 May; 18(5):528-32. doi:
10.1111/dom.12631. [PMID: 26749529] - Shinichiro Kimura, Toyoshi Inoguchi, Toshihide Yamasaki, Mayumi Yamato, Makoto Ide, Noriyuki Sonoda, Kenichi Yamada, Ryoichi Takayanagi. A novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: In vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 deficient rats.
Metabolism: clinical and experimental.
2016 Mar; 65(3):138-45. doi:
10.1016/j.metabol.2015.10.030. [PMID: 26892525] - Chihiro Moriya, Hiroaki Satoh. Teneligliptin Decreases Uric Acid Levels by Reducing Xanthine Dehydrogenase Expression in White Adipose Tissue of Male Wistar Rats.
Journal of diabetes research.
2016; 2016(?):3201534. doi:
10.1155/2016/3201534. [PMID: 27652270] - Takayasu Ideta, Yohei Shirakami, Tsuneyuki Miyazaki, Takahiro Kochi, Hiroyasu Sakai, Hisataka Moriwaki, Masahito Shimizu. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.
International journal of molecular sciences.
2015 Dec; 16(12):29207-18. doi:
10.3390/ijms161226156. [PMID: 26670228] - Noritsugu Wada, Katsuhito Mori, Chie Nakagawa, Jun Sawa, Yasuro Kumeda, Tetsuo Shoji, Masanori Emoto, Masaaki Inaba. Improved glycemic control with teneligliptin in patients with type 2 diabetes mellitus on hemodialysis: Evaluation by continuous glucose monitoring.
Journal of diabetes and its complications.
2015 Nov; 29(8):1310-3. doi:
10.1016/j.jdiacomp.2015.07.002. [PMID: 26298521] - M Kusunoki, D Sato, T Nakamura, Y Oshida, H Tsutsui, Y Natsume, K Tsutsumi, T Miyata. DPP-4 Inhibitor Teneligliptin Improves Insulin Resistance and Serum Lipid Profile in Japanese Patients with Type 2 Diabetes.
Drug research.
2015 Oct; 65(10):532-4. doi:
10.1055/s-0034-1390419. [PMID: 25368904] - Azusa Sameshima, Tsutomu Wada, Tetsuo Ito, Ayaka Kashimura, Kanae Sawakawa, Rika Yonezawa, Hiroshi Tsuneki, Yoko Ishii, Masakiyo Sasahara, Shigeru Saito, Toshiyasu Sasaoka. Teneligliptin improves metabolic abnormalities in a mouse model of postmenopausal obesity.
The Journal of endocrinology.
2015 Oct; 227(1):25-36. doi:
10.1530/joe-15-0239. [PMID: 26264980] - S Shantikumar, N Satheeshkumar, R Srinivas. Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor - Teneligliptin in rats using liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2015 Oct; 1002(?):194-200. doi:
10.1016/j.jchromb.2015.08.023. [PMID: 26340762] - Rika Ito, Tomoyasu Fukui, Toshiyuki Hayashi, Anna Osamura, Makoto Ohara, Noriko Hara, Akiko Higuchi, Takeshi Yamamoto, Tsutomu Hirano. Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.
Drugs in R&D.
2015 Sep; 15(3):245-51. doi:
10.1007/s40268-015-0096-6. [PMID: 26224337] - Masao Moroi, Tetsuya Kubota. Diuretic and Natriuretic Effects of Dipeptidyl Peptidase-4 Inhibitor Teneligliptin: The Contribution of Glucagon-like Peptide-1.
Journal of cardiovascular pharmacology.
2015 Aug; 66(2):159-64. doi:
10.1097/fjc.0000000000000258. [PMID: 25853991] - Takahiro Oguma, Chiaki Kuriyama, Keiko Nakayama, Yasuaki Matsushita, Kumiko Yoshida, Satoko Kiuchi, Yuka Ikenaga, Yoshinobu Nakamaru, Kumiko Hikida, Akira Saito, Kenji Arakawa, Kozo Oka, Kiichiro Ueta, Masaharu Shiotani. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
Journal of pharmacological sciences.
2015 Apr; 127(4):456-61. doi:
10.1016/j.jphs.2015.03.006. [PMID: 25892328] - Yoshinobu Nakamaru, Chie Emoto, Makiko Shimizu, Hiroshi Yamazaki. Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling.
Biopharmaceutics & drug disposition.
2015 Apr; 36(3):148-62. doi:
10.1002/bdd.1928. [PMID: 25450725] - M K Kim, E-J Rhee, K A Han, A C Woo, M-K Lee, B J Ku, C H Chung, K-A Kim, H W Lee, I B Park, J Y Park, H C Chul Jang, K S Park, W I Jang, B Y Cha. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial.
Diabetes, obesity & metabolism.
2015 Mar; 17(3):309-12. doi:
10.1111/dom.12424. [PMID: 25475929] - Kazunari Kamiko, Kazutaka Aoki, Hiroshi Kamiyama, Masataka Taguri, Eriko Shibata, Yumiko Ashiya, Fuyuki Minagawa, Kazuaki Shinoda, Shigeru Nakajima, Yasuo Terauchi. Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: a randomized non-inferior test.
Journal of clinical pharmacology.
2015 Feb; 55(2):144-51. doi:
10.1002/jcph.385. [PMID: 25159300] - Wakaba Tsuchimochi, Hiroaki Ueno, Eiichiro Yamashita, Chikako Tsubouchi, Hideyuki Sakoda, Shuji Nakamura, Masamitsu Nakazato. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Endocrine journal.
2015; 62(1):13-20. doi:
10.1507/endocrj.ej14-0393. [PMID: 25252844] - Shuji Kinoshita, Kazuoki Kondo. Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers.
Expert opinion on drug metabolism & toxicology.
2015 Jan; 11(1):7-14. doi:
10.1517/17425255.2015.982531. [PMID: 25424014] - Seiichi Tanaka, Kunihiro Suzuki, Chie Aoki, Mai Niitani, Kanako Kato, Takanori Tomotsune, Yoshimasa Aso. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
Diabetes technology & therapeutics.
2014 Dec; 16(12):840-5. doi:
10.1089/dia.2014.0095. [PMID: 25144424] - Atef Halabi, Haidar Maatouk, Karl Ernst Siegler, Nadja Faisst, Holger Hinrichsen. Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment.
Clinical pharmacology in drug development.
2014 07; 3(4):290-6. doi:
10.1002/cpdd.89. [PMID: 27128835] - T Kadowaki, K Kondo. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
Diabetes, obesity & metabolism.
2014 May; 16(5):418-25. doi:
10.1111/dom.12235. [PMID: 24205974] - Yoshinobu Nakamaru, Yoshiharu Hayashi, Mana Sekine, Shuji Kinoshita, Jeff Thompson, Atsuhiro Kawaguchi, Martin Davies, Horst Jürgen Heuer, Hiroshi Yamazaki, Kei Akimoto. Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany.
Clinical therapeutics.
2014 May; 36(5):760-9. doi:
10.1016/j.clinthera.2014.03.002. [PMID: 24726088] - Yoshinobu Nakamaru, Yoshiharu Hayashi, Ruriko Ikegawa, Shuji Kinoshita, Begonya Perez Madera, Dave Gunput, Atsuhiro Kawaguchi, Martin Davies, Stuart Mair, Hiroshi Yamazaki, Toshiyuki Kume, Masayuki Suzuki. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans.
Xenobiotica; the fate of foreign compounds in biological systems.
2014 Mar; 44(3):242-53. doi:
10.3109/00498254.2013.816891. [PMID: 23855261] - Hideo Otsuki, Takeo Kosaka, Kenzo Nakamura, Fumihiko Shimomura, Yoshitaka Kuwahara, Takuji Tsukamoto. Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.
International urology and nephrology.
2014 Feb; 46(2):427-32. doi:
10.1007/s11255-013-0552-6. [PMID: 24014134] - Sayaka Fukuda-Tsuru, Tetsuhiro Kakimoto, Hiroyuki Utsumi, Satoko Kiuchi, Shinichi Ishii. The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice.
European journal of pharmacology.
2014 Jan; 723(?):207-15. doi:
10.1016/j.ejphar.2013.11.030. [PMID: 24309217] - M Goda, T Kadowaki. Teneligliptin for the treatment of type 2 diabetes.
Drugs of today (Barcelona, Spain : 1998).
2013 Oct; 49(10):615-29. doi:
10.1358/dot.2013.49.10.2035882. [PMID: 24191255] - T Kadowaki, K Kondo. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Diabetes, obesity & metabolism.
2013 Sep; 15(9):810-8. doi:
10.1111/dom.12092. [PMID: 23464664] - Sayaka Fukuda-Tsuru, Jun Anabuki, Yuji Abe, Kumiko Yoshida, Shinichi Ishii. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
European journal of pharmacology.
2012 Dec; 696(1-3):194-202. doi:
10.1016/j.ejphar.2012.09.024. [PMID: 23022337] - T Eto, S Inoue, T Kadowaki. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial.
Diabetes, obesity & metabolism.
2012 Nov; 14(11):1040-6. doi:
10.1111/j.1463-1326.2012.01662.x. [PMID: 22776014] - Tomohiro Yoshida, Fumihiko Akahoshi, Hiroshi Sakashita, Hiroshi Kitajima, Mitsuharu Nakamura, Shuji Sonda, Masahiro Takeuchi, Yoshihito Tanaka, Naoko Ueda, Sumie Sekiguchi, Takayuki Ishige, Kyoko Shima, Mika Nabeno, Yuji Abe, Jun Anabuki, Aki Soejima, Kumiko Yoshida, Yoko Takashina, Shinichi Ishii, Satoko Kiuchi, Sayaka Fukuda, Reiko Tsutsumiuchi, Keigo Kosaka, Takahiro Murozono, Yoshinobu Nakamaru, Hiroyuki Utsumi, Naoya Masutomi, Hiroyuki Kishida, Ikuko Miyaguchi, Yoshiharu Hayashi. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Bioorganic & medicinal chemistry.
2012 Oct; 20(19):5705-19. doi:
10.1016/j.bmc.2012.08.012. [PMID: 22959556] - G Walldius, P Rubba. A micro-method for determination of fatty acid (FIAT) and glucose (GLIAT) incorporation and lipolysis in vitro in needle biopsies of human adipose tissue.
Scandinavian journal of clinical and laboratory investigation.
1976 Jul; 36(4):357-69. doi:
10.3109/00365517609055271. [PMID: 8829]